Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Francesca, Cunningham"'
Autor:
Suzette A. Rovelsky, Michelle Vu, Alexis K. Barrett, Kenneth Bukowski, Xiangming Wei, Muriel Burk, Makoto Jones, Kelly Echevarria, Katie J Suda, Francesca Cunningham, Karl J Madaras-Kelly, for the UTI Management Improvement Group
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 2 (2022)
Abstract Objective: To conduct a contemporary detailed assessment of outpatient antibiotic prescribing and outcomes for positive urine cultures in a mixed-sex cohort. Design: Multicenter retrospective cohort review. Setting: The study was conduc
Externí odkaz:
https://doaj.org/article/f17cb797cc354788ad26fc7604ed22e8
Autor:
Ashir, Shumunov, Paul, Fina, Jennifer, Martin, Alexis, Barrett, Kelly, Echevarria, Francesca, Cunningham
Publikováno v:
American Journal of Health-System Pharmacy. 80:518-525
Purpose The purpose of this project was to develop and optimize a dashboard and registry to manage the distribution, utilization, and monitoring of coronavirus disease 2019 (COVID-19) emergency use–authorized medications (CEUAMs). Summary CEUAMs ha
Autor:
Jing Luo, Kwan Hur, Cedric Salone, Nina Huang, Muriel Burk, Lucy Pandey, Bharat Thakkar, Mark Donahue, Francesca Cunningham
Publikováno v:
Open Forum Infectious Diseases.
Background Although the benefits outweigh risks, COVID-19 vaccines have been associated with an increased risk of myocarditis and pericarditis. This is a national US Veteran population-based report of confirmed myocarditis/pericarditis following mRNA
Autor:
Lei Yan, Elani Streja, Yuli Li, Nallakkandi Rajeevan, Mazhgan Rowneki, Kristin Berry, Denise M. Hynes, Francesca Cunningham, Grant D. Huang, Mihaela Aslan, George N. Ioannou, Kristina L. Bajema
IMPORTANCESeveral pharmacotherapies have been authorized to treat non-hospitalized persons with symptomatic COVID-19. Longitudinal information on their use is needed.OBJECTIVETo analyze trends and factors related to prescription of outpatient COVID-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6eee29f38a86347d8c76c259f9a81ec
https://doi.org/10.1101/2023.05.03.23289479
https://doi.org/10.1101/2023.05.03.23289479
Autor:
Kristina L. Bajema, Kristin Berry, Elani Streja, Nallakkandi Rajeevan, Yuli Li, Lei Yan, Francesca Cunningham, Denise M. Hynes, Mazhgan Rowneki, Amy Bohnert, Edward J. Boyko, Theodore J. Iwashyna, Matthew L. Maciejewski, Thomas F. Osborne, Elizabeth M. Viglianti, Mihaela Aslan, Grant D. Huang, George N. Ioannou
Publikováno v:
medRxiv
BackgroundInformation about the effectiveness of oral antivirals in preventing short- and long-term COVID-19-related outcomes during the Omicron surge is limited. We sought to determine the effectiveness of nirmatrelvir-ritonavir and molnupiravir for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c61d5bec90cc9a62c00361d3c8d757
https://doi.org/10.1101/2022.12.05.22283134
https://doi.org/10.1101/2022.12.05.22283134
Autor:
Kristina L. Bajema, Xiao Qing Wang, Denise M. Hynes, Mazhgan Rowneki, Alex Hickok, Francesca Cunningham, Amy Bohnert, Edward J. Boyko, Theodore J. Iwashyna, Matthew L. Maciejewski, Elizabeth M. Viglianti, Elani Streja, Lei Yan, Mihaela Aslan, Grant D. Huang, George N. Ioannou
Publikováno v:
JAMA network open. 5(11)
ImportanceOlder adults and individuals with medical comorbidities are at increased risk for severe COVID-19. Several pharmacotherapies demonstrated to reduce the risk of COVID-19–related hospitalization and death have been authorized for use.Object
Autor:
Kristina L. Bajema, Xiao Qing Wang, Denise M. Hynes, Mazhgan Rowneki, Alex Hickok, Francesca Cunningham, Amy Bohnert, Edward J. Boyko, Theodore J. Iwashyna, Matthew L. Maciejewski, Elizabeth M. Viglianti, Elani Streja, Lei Yan, Mihaela Aslan, Grant D. Huang, George N. Ioannou
BackgroundOlder adults and persons with medical co-morbidities are at increased risk for severe COVID-19. Several pharmacotherapies demonstrated to reduce the risk of COVID-19-related hospitalization and death have been authorized for use. We describ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2501559fca701069e0f15188b25e6c0d
https://doi.org/10.1101/2022.06.22.22276782
https://doi.org/10.1101/2022.06.22.22276782
Autor:
Joseph T DiPiro, Jannet M Carmichael, Vivian B Johnson, Monika N Daftary, Leyner Martinez, Michelle D Wiest, Binita Patel, Tom Woller, Elva Angelique Van Devender, Rita Shane, Francesca Cunningham
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 79(2)
Publikováno v:
American Journal of Psychiatry. 173:896-902
Objective:A public safety communication issued by the Food and Drug Administration declared that citalopram dosages exceeding 40 mg/day were no longer considered safe because of a newly recognized risk of dosage-dependent QT interval prolongation. Th
Autor:
Rumeng Li, Baotian Hu, Feifan Liu, Weisong Liu, Francesca Cunningham, David D McManus, Hong Yu
BACKGROUND Bleeding events are common and critical and may cause significant morbidity and mortality. High incidences of bleeding events are associated with cardiovascular disease in patients on anticoagulant therapy. Prompt and accurate detection of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ce951dbc438a77953959cbca5d1d214
https://doi.org/10.2196/preprints.10788
https://doi.org/10.2196/preprints.10788